TOKYO - Japan's Kissei Pharmaceutical Co. has started urging doctors to refrain from using Tavneos, a drug used to treat rare kidney diseases, for new patients after 20 deaths possibly linked to the treatment were reported in Japan.
Sorry. This article is no longer available.
Sorry, this article was first published more than three months ago and is temporarily unavailable.
Once the upcoming introduction of a paid membership system is fully operational, paid members will have access to all our stories.
Free Membership Provides
Newsletter from Editorial Team and access to archive articles from past three months.
By continuing, you agree to the Terms of Use,
and Privacy Policy.
Related coverage:
